SNRK tames mTOR against metabolic dysfunction-associated steatotic liver disease.
作者信息
Brunetti-Pierri Nicola, Bewersdorf Lisa, Strnad Pavel
机构信息
Department of Translational Medicine, Federico II University, Naples, Italy; Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy; Genomics and Experimental Medicine Program, Scuola Superiore Meridionale (SSM, School of Advanced Studies), Naples, Italy.
Medical Clinic III, Gastroenterology, Metabolic Diseases, and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
出版信息
Mol Ther. 2025 Jan 8;33(1):28-29. doi: 10.1016/j.ymthe.2024.12.031. Epub 2024 Dec 26.
Abstract
摘要
相似文献
1
SNRK tames mTOR against metabolic dysfunction-associated steatotic liver disease.丝氨酸/苏氨酸蛋白激酶（SNRK）抑制哺乳动物雷帕霉素靶蛋白（mTOR），以对抗代谢功能障碍相关的脂肪性肝病。
Mol Ther. 2025 Jan 8;33(1):28-29. doi: 10.1016/j.ymthe.2024.12.031. Epub 2024 Dec 26.
2
SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD.丝氨酸/苏氨酸蛋白激酶相关激酶（SNRK）调节mTOR-自噬途径以维持非酒精性脂肪性肝病（MAFLD）中的肝脏脂质稳态。
Mol Ther. 2025 Jan 8;33(1):279-296. doi: 10.1016/j.ymthe.2024.11.016. Epub 2024 Nov 9.
3
Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data.女性生殖因素与代谢功能障碍相关脂肪性肝病：一项基于人群队列、肝脏影像学和基因数据的综合分析
Am J Obstet Gynecol. 2025 Apr 29. doi: 10.1016/j.ajog.2025.04.007.
4
Menopause and metabolic dysfunction-associated steatotic liver disease.绝经与代谢功能紊乱相关的脂肪性肝病。
Maturitas. 2024 Aug;186:108024. doi: 10.1016/j.maturitas.2024.108024. Epub 2024 May 14.
5
Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center.代谢相关脂肪性肝病在三级中心炎症性肠病中的患病率及相关危险因素。
Rev Assoc Med Bras (1992). 2024 Jul 19;70(6):e20231321. doi: 10.1590/1806-9282.20231321. eCollection 2024.
6
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease.酒精摄入与代谢功能障碍相关脂肪性肝病和代谢功能障碍及酒精相关肝病中与心血管代谢因素和肝纤维化的关联。
Aliment Pharmacol Ther. 2024 Dec;60(11-12):1587-1598. doi: 10.1111/apt.18280. Epub 2024 Sep 23.
7
The therapeutic potential of different mesenchymal stem cells and their derived exosomes in metabolic dysfunction-associated steatotic liver disease.不同间充质干细胞及其衍生外泌体在代谢功能障碍相关脂肪性肝病中的治疗潜力。
Front Endocrinol (Lausanne). 2025 Apr 3;16:1558194. doi: 10.3389/fendo.2025.1558194. eCollection 2025.
8
Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases.蛋白质组学变异是代谢功能障碍相关脂肪性肝病发展为后续慢性疾病的异质性风险的基础。
Eur J Endocrinol. 2025 Apr 30;192(5):691-703. doi: 10.1093/ejendo/lvaf103.
9
A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.用于检测代谢功能障碍相关脂肪性肝病患者显著纤维化的非侵入性检测组合并不优于单独使用磁共振弹性成像。
Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.
10
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.肝移植后代谢功能障碍相关脂肪性肝病（MASLD）：一个新出现问题的叙述性综述
J Clin Med. 2024 Jun 30;13(13):3871. doi: 10.3390/jcm13133871.
本文引用的文献
1
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).代谢功能障碍相关脂肪性肝炎（MASH）的治疗前景
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
2
SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD.丝氨酸/苏氨酸蛋白激酶相关激酶（SNRK）调节mTOR-自噬途径以维持非酒精性脂肪性肝病（MAFLD）中的肝脏脂质稳态。
Mol Ther. 2025 Jan 8;33(1):279-296. doi: 10.1016/j.ymthe.2024.11.016. Epub 2024 Nov 9.
3
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics.呼吁调整基于T细胞受体疗法的人类白细胞抗原（HLA）检测监管。
Nat Rev Drug Discov. 2024 Jan;23(1):1-2. doi: 10.1038/d41573-023-00189-4.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
5
Rare ATG7 genetic variants predispose patients to severe fatty liver disease.罕见的 ATG7 基因突变使患者易患严重的脂肪肝疾病。
J Hepatol. 2022 Sep;77(3):596-606. doi: 10.1016/j.jhep.2022.03.031. Epub 2022 Apr 9.
6
mTOR at the nexus of nutrition, growth, ageing and disease.mTOR 在营养、生长、衰老和疾病的交汇点。
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203. doi: 10.1038/s41580-019-0199-y. Epub 2020 Jan 14.
7
Dysregulation of PP2A-Akt interaction contributes to Sucrose non-fermenting related kinase (SNRK) deficiency induced insulin resistance in adipose tissue.PP2A-Akt 相互作用失调导致脂肪组织中蔗糖非发酵相关激酶（SNRK）缺乏诱导的胰岛素抵抗。
Mol Metab. 2019 Oct;28:26-35. doi: 10.1016/j.molmet.2019.07.009. Epub 2019 Aug 2.
8
Autophagy in liver diseases: Time for translation?肝脏疾病中的自噬：是否到了转化的时机？
J Hepatol. 2019 May;70(5):985-998. doi: 10.1016/j.jhep.2019.01.026. Epub 2019 Jan 31.
9
Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap.自噬通过控制 Yap 的降解来充当肝分化和癌变的守门员。
Nat Commun. 2018 Nov 23;9(1):4962. doi: 10.1038/s41467-018-07338-z.
10
Identification of sucrose non-fermenting-related kinase (SNRK) as a suppressor of adipocyte inflammation.鉴定蔗糖非发酵相关激酶（SNRK）为脂肪细胞炎症的抑制物。
Diabetes. 2013 Jul;62(7):2396-409. doi: 10.2337/db12-1081. Epub 2013 Mar 21.
Zotero 插件